Observational studyFrontiers in neurology2026
Real-world effectiveness and safety of lasmiditan in patients with migraine: an observational study.
Observational study in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the real-world effectiveness and safety of lasmiditan and determine the factors associated with its effectiveness and adverse effects. Methods: We evaluated 75 migraine patients (15 males and 60 females; age 44.0 ± 12.4 years), including 20 (35.1%) with chronic migraine, who completed a questionnaire in a single-center setting. Headache severity before and after taking lasmiditan was scored using a numerical rating scale (NRS), and changes in pain and most bothersome symptoms (MBS) were assessed over time. Adverse effects such as drowsiness, weakness, and dizziness, as well as preferences, were also evaluated. Results: The response rate was 76% (57/75 patients, 180 attacks). Headache improvement was observed in 61.3% (100/144 attacks) at 2 h and 73.0% (119/151 attacks) at 24 h, with headache resolution rates of 27.8% (50/144 attacks) and 43.9% (71/151 attacks), respectively. Compared with patients who did not receive anti-CGRP monoclonal antibodies, patients who received anti-CGRP monoclonal antibodies had higher 2-h headache improvement rates (77.0% vs. 57.9%, Conclusion: Lasmiditan demonstrated meaningful effectiveness in a real-world setting, although adverse effects were common.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.